Patents by Inventor Ditte Riber

Ditte Riber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glucagon analogues
    Patent number: 8685919
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: April 1, 2014
    Assignee: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
  • Glucagon analogues
    Patent number: 8680049
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: March 25, 2014
    Assignee: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
  • GLUCAGON ANALOGUES
    Publication number: 20140080757
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: September 17, 2013
    Publication date: March 20, 2014
    Applicants: Boehringer Ingelheim International GmbH, Zealand Pharma A/S
    Inventors: Jakob Lind TOLBORG, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas
  • Glucagon analogues
    Patent number: 8642540
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: February 4, 2014
    Assignee: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
  • Glucagon analogues
    Patent number: 8642541
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: February 4, 2014
    Assignee: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
  • COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES
    Publication number: 20140011733
    Abstract: The invention relates to methods for treating metabolic disorders, including diabetes by using a combination of an acylated glucagon analogue and an insulin analogue. The invention also features a kit that includes an acylated glucagon analogue and an insuline analogue.
    Type: Application
    Filed: January 20, 2012
    Publication date: January 9, 2014
    Applicant: Zealand Pharma A/S
    Inventors: Keld Fosgerau, Ditte Riber
  • GLUCAGON ANALOGUES
    Publication number: 20130316941
    Abstract: The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes. The compounds may mediate their effect, inter alia, by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: December 19, 2012
    Publication date: November 28, 2013
    Applicants: Boehringer Ingelheim International GmbH, Zealand Pharma A/S
    Inventors: Dieter Wolfgang Hamprecht, Jakob Lind Tolborg, Ditte Riber
  • GLUCAGON ANALOGUES
    Publication number: 20130157929
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain and for treating diabetes and associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptide compounds effective in such methods. The compounds may mediate their effect by having, for example, increased selectivity for the GLP-1 receptor compared to human glucagon.
    Type: Application
    Filed: June 24, 2011
    Publication date: June 20, 2013
    Applicant: ZEALAND PHARMA A/S
    Inventors: Ditte Riber, Eddi Meier
  • GLUCAGON ANALOGUES
    Publication number: 20130157935
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: June 23, 2011
    Publication date: June 20, 2013
    Applicant: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Jens Rosengren Daugaard, Marie Skovgaard
  • TREATMENT OF CARDIAC CONDITIONS
    Publication number: 20130157953
    Abstract: The invention relates to the treatment of cardiac dysfunction. In particular, certain compounds, believed to be glucagon-GLP-1 dual agonist compounds, exert a positive inotropic effect while preserving the energy balance of the heart, and so may be superior to known inotropic agents such as dobutamine, norepinephrine and glucagon.
    Type: Application
    Filed: January 20, 2011
    Publication date: June 20, 2013
    Applicant: Zealand Pharma A/S
    Inventors: Jørgen Søberg Petersen, Anne Louise Kjoelbye, Marie Skovgaard, Henrik Duelund Pedersen, Lene Axelsen, Ditte Riber, Eddi Meier, Rie Schultz Hansen, Keld Fosgerau, Bjarne Due Larsen
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20120178670
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: June 24, 2010
    Publication date: July 12, 2012
    Applicant: Zealand Pharma A/S
    Inventors: Ditte Riber, Eddi Meier, Jens Rosengren Daugaard, Marie Skovgaard, Jakob Lind Tolborg, Gita Kampen, Camilla Ærteberg Bæk
  • GLUCAGON ANALOGUES
    Publication number: 20110293586
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: December 15, 2008
    Publication date: December 1, 2011
    Applicant: ZEALAND PHARMA A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengern Daugaard
  • GLUCAGON ANALOGUES
    Publication number: 20110293587
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: December 15, 2008
    Publication date: December 1, 2011
    Applicant: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
  • GLUCAGON ANALOGUES
    Publication number: 20110286981
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: December 15, 2008
    Publication date: November 24, 2011
    Applicant: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
  • GLUCAGON ANALOGUES
    Publication number: 20110286982
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: December 15, 2008
    Publication date: November 24, 2011
    Applicant: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
  • Glucagon analogues
    Patent number: 7994122
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain in a subject. In particular, the invention provides novel glucagon analogue peptides effective in such methods and in the treatment of obesity, eating disorders, metabolic syndrome, and non-alcoholic liver steatosis. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: August 9, 2011
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Eddi Meier, Trine Skovlund Ryge, Jens Rosengren Daugaard
  • GLUCAGON ANALOGUES
    Publication number: 20100204105
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain in a subject. In particular, the invention provides novel glucagon analogue peptides effective in such methods and in the treatment of obesity, eating disorders, metabolic syndrome, and non-alcoholic liver steatosis. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: June 16, 2008
    Publication date: August 12, 2010
    Applicant: Zealand Pharma A/S
    Inventors: Ditte Riber, Eddi Meier, Trine Skovlund Ryge, Jens Rosengren Daugaard